Topical RNA Needs More Than Penetration
Fluorescence, target knockdown, and patient outcomes answer different questions. Topical RNA studies show why each needs its own evidence.
A signal in skin is a beginning
RNA must reach the relevant cells and remain functional there. A recent androgen-receptor study combined an asymmetric siRNA with an ionic-liquid–liposome carrier. The researchers tracked fluorescent material in excised pig skin and measured androgen-receptor knockdown in cultured human dermal papilla cells. Those experiments address tissue distribution and cellular activity separately. They do not demonstrate both in the same human follicle. [1]
The authors also reported a 28-day, open-label observation in volunteers with hair loss or acne. Without randomization, blinding, or a placebo group, the reported changes cannot establish treatment efficacy. A lower hair-shedding count is not the same measurement as increased hair density. [1]
The tissue changes the question
Earlier work with elastic liposomes compared excised normal human skin and psoriatic lesional skin. A comparator formulation showed different distribution across the two tissue states. In a separate reconstructed psoriasis model, siRNA delivery was associated with reduced target expression. Distribution in excised skin and functional response in a model are useful results, but neither is a patient outcome. [2]
The distinction has a clinical precedent. In historical AST-005 studies, Exicure reported a reduction in a target mRNA measure from psoriasis-lesion biopsies at the highest concentration. The company also stated that clinical antipsoriatic efficacy was not demonstrated. In a later Phase 1b disclosure, a lesion ultrasound measure did not show a statistically significant reduction. These disclosures do not identify why the clinical result differed from the molecular readout. [3, 4]
For topical RNA development, the next experiment depends on the unanswered question: where the material goes, whether intact RNA produces a local cellular effect, or whether that effect changes a patient outcome. Each step needs its own readout and comparison. Evidence from one step cannot stand in for the next.